Please login to the form below
Merck enters Alzheimer's partnership
Merck has entered into a $289m research partnership with Alectos Therapeutics
Merck has entered into a research partnership with Alectos Therapeutics focused on compounds that modulate the enzyme -linked N-acetylglucosaminidase (O-GlcNAcase).
The deal, which is valued at $289m, gives Merck exclusive global rights to research, develop and commercialise compounds that modulate the target in return for an upfront payment, milestones, royalties, and research funding for Alectos' existing portfolio of compounds targeting Alzheimer's disease.
The agreement calls for Alectos and Merck to partner on discovery and preclinical development, with Merck taking over full responsibility for clinical development. The companies may also develop products that modulate the enzyme as treatments for other neurological diseases.
Alectos was founded by researchers from Canada's Simon Frasier University.
Share
Related Hub content
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
